Get the Stockscreener App
17.29
3.57%
-0.64
After Hours:
17.29
Arcturus Therapeutics Holdings Inc Stock (ARCT) Latest News
Arcturus Therapeutics names Moncef Slaoui as Chair Designate - MSN
State Street Corp Reduces Holdings in Arcturus Therapeutics Holdings Inc - GuruFocus.com
Global mRNA Vaccines and Therapeutics Market is expected - openPR
Arcturus Therapeutics Appoints Moncef Slaoui Chair Designate -February 04, 2025 at 10:40 am EST - Marketscreener.com
Arcturus Therapeutics' SWOT analysis: mRNA innovator's stock faces pivotal year - MSN
Arcturus Therapeutics names Moncef Slaoui as Chair Designate By Investing.com - Investing.com UK
Vaccine Pioneer Moncef Slaoui Takes Helm at Arcturus Ahead of Critical Pipeline Milestones - StockTitan
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Short Interest Up 8.6% in January - MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Now Covered by Analysts at BTIG Research - MarketBeat
Japan's COVID Vaccine Independence: Meiji Gets Green Light for Local KOSTAIVE Production - StockTitan
Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference - BioSpace
BTIG Research Begins Coverage on Arcturus Therapeutics (NASDAQ:ARCT) - Defense World
ARCT (Arcturus Therapeutics Holdings) Cash-to-Debt : 8.06 (As of Sep. 2024) - GuruFocus.com
Arcturus: Downgrading As mRNA Promise Meets Market Reality (NASDAQ:ARCT) - Seeking Alpha
Demystifying Arcturus Therapeutics: Insights From 5 Analyst Reviews - Benzinga
BTIG Initiates Arcturus Therapeutics Holdings at Buy With $41 Price Target -January 28, 2025 at 07:27 am EST - Marketscreener.com
Leerink Partnrs Has Positive Outlook of ARCT FY2024 Earnings - Defense World
What is Leerink Partnrs' Forecast for ARCT FY2024 Earnings? - MarketBeat
Cantor Fitzgerald Forecasts ARCT FY2025 Earnings - Defense World
Q3 Earnings Estimate for ARCT Issued By Leerink Partnrs - Defense World
Q3 Earnings Forecast for ARCT Issued By Leerink Partnrs - MarketBeat
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $66.75 Consensus Target Price from Analysts - Defense World
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Sees Significant Increase in Short Interest - Defense World
Hennion & Walsh Asset Management Inc. Acquires 47,824 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Earns Buy Rating from HC Wainwright - Defense World
Arcturus Therapeutics (NASDAQ:ARCT) Receives Buy Rating from HC Wainwright - MarketBeat
Arcturus Therapeutics launches Phase I Avian Influenza trials in US - Yahoo Finance
Arcturus Launches Phase 1 Trial for Next-Gen H5N1 Flu Vaccine with BARDA Funding - StockTitan
Arcturus Therapeutics Holdings Inc (ARCT) Recovers 32.52% From Low: Are We There Yet? - Stocks Register
HC Wainwright Reiterates Buy Rating for Arcturus Therapeutics (NASDAQ:ARCT) - Defense World
Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Down 8.6%Should You Sell? - MarketBeat
Arcturus Therapeutics' SWOT analysis: sa-mRNA stock poised for growth amid challenges - Investing.com India
Arcturus up 9% as phase 2 dosing begins for mRNA asset for cystic fibrosis - MSN
Arcturus Therapeutics (NASDAQ:ARCT) Trading 5.9% HigherWhat's Next? - MarketBeat
Arcturus Therapeutics' (ARCT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency - Business Wire
Arcturus Therapeutics Advances Phase 2 Trials for Breakthrough CF and OTC Deficiency Treatments - StockTitan
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Acquired by Geode Capital Management LLC - Defense World
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $66.75 Consensus Price Target from Analysts - Defense World
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock Holdings Increased by Franklin Resources Inc. - Defense World
Franklin Resources Inc. Acquires 36,714 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Head-To-Head Survey: Zymeworks (NYSE:ZYME) versus Arcturus Therapeutics (NASDAQ:ARCT) - Defense World
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):